<DOC>
	<DOCNO>NCT02339207</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , 3-part study ass safety , tolerability , pharmacokinetics orally administer AL-335 healthy volunteer ( HV ) subject CHC infection .</brief_summary>
	<brief_title>First Human Study AL-335 ; Single Dose , Food Effect Healthy Volunteers ; Multiple Doses Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Subject provide write consent . In investigator 's opinion , subject able understand comply protocol requirement , instruction , protocol state restriction likely complete study plan . Subject good health deem investigator , base finding medical evaluation include medical history , physical examination , laboratory test , ECG . Male female , 1860 year age HV 1865 year age subject CHC . Body mass index ( BMI ) 1832 kg/m2 , inclusive , HV 1835 kg/m2 , inclusive , subject CHC . The minimum weight 50 kg population . No 25 % patient cohort may enrol BMI ≥ 30 kg/m2 . A female subject eligible participate study non childbearing potential ( defined female document tubal ligation , bilateral oophorectomy , hysterectomy ) postmenopausal ( defined 12 month spontaneous amenorrhea follicle stimulate hormone ( FSH ) level within laboratory 's reference range postmenopausal female ) . A postmenopausal female receive hormone replacement therapy willing discontinue hormone therapy 28 day study drug dose agrees remain hormone replacement therapy duration study may eligible study participation . If male , subject surgically sterile practice specific form birth control ( outline Section 6.2.9 ) 90 day end study . Additional inclusion criterion subject CHC infection : Documentation Genotype 1 HCV infection great 6 month dose Screening HCV RNA viral load ≥ 105 IU/mL use sensitive quantitative assay , COBAS® Taqman® HCV Test 2.0 1 . Clinically significant cardiovascular , respiratory , renal , gastrointestinal , hematologic , neurologic , thyroid , medical illness psychiatric disorder , determine Investigator and/or Sponsor 's Medical Monitor . 2 . Positive test HAV IgM , HBsAg , HIV Ab . In Parts 1 2 positive HCV serology exclusionary . 3 . Any condition , opinion investigator , would compromise study 's objective wellbeing subject prevent subject meeting study requirement . 4 . Participation investigational drug trial receive investigational vaccine within 30 day 5 half life ( whichever longer ) prior study medication . 5 . Clinically significant abnormal ECG finding . Particularly , history family history prolong QT syndrome ( e.g. , torsade de pointes ) sudden cardiac death ; correct QT interval ( QTc ) &gt; 450 millisecond male subject &gt; 470 millisecond female subject Screening Visit . 6 . Clinically significant blood loss elective blood donation significant volume ( i.e. , &gt; 500 mL ) within 60 day first dose study drug ; &gt; 1 unit plasma within 7 day first dose study drug . 7 . Abnormal heart rate , respiratory rate , temperature blood pressure value outside normal range ( evaluated semirecumbent recumbent position 5 minute rest ) . One repeat measurement additional 5 minute rest permit . 8 . Evidence active infection ( CHC infection subject enrol Part 3 ) . 9 . Unwilling abstain alcohol 48 hour prior start dose study completion visit . 10 . History regular alcohol intake &gt; 7 unit per week alcohol female &gt; 14 unit per week male ( one unit define 10 g alcohol ) within 3 month screen visit . 11 . For healthy subject ( Parts 12 ) , history regular use tobacco ( i.e. , ≥10 cigarette per day ) nicotinecontaining product within 3 month screen visit . For subject CHC infection , history regular use tobacco nicotinecontaining product allow . 12 . The subject positive prestudy drug screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids , phencyclidine ( PCP ) benzodiazepine . Subjects CHC may include positive result cannabinoids screen . However , must willing abstain cannabinoid use throughout duration study . 13 . In Parts 12 , use concomitant medication , include prescription , counter medication , herbal medication within 14 day prior first dose study medication exclude , unless approve Sponsor 's Medical Monitor . PRN use nonsteroidal anti inflammatory drug ( NSAID ) permit . 14 . For subject Part 3 , use prescription counter medication deem necessary maintain health status subject permit , approve Sponsor 's Medical Monitor . PRN NSAID use permit . Further guidance use prior medication subject CHC find Section 5.7 . 15 . Subjects must receive drug know strong inducer inhibitor CYP450 enzymes within 2 week prior study drug dosing ( Appendix C ) . 16 . Exposure four new investigational entity within 12 month prior first dose day . 17 . Abnormal biochemistry hematology laboratory result obtain screen . Elevated bilirubin subject suspect Gilbert 's disease allow . Additional exclusion criterion subject CHC infection : 18 . History clinical hepatic decompensation , e.g. , variceal bleeding , spontaneous bacterial peritonitis , ascites , hepatic encephalopathy active jaundice 19 . Liver biopsy within two year Fibroscan evaluation within 6 month prior randomization demonstrate cirrhosis ( Knodell score &gt; 3 , Metavir score &gt; 3 , Ishak score &gt; 4 ) . Fibroscan liver stiffness score &gt; 10.5 kPa . 20 . Prior treatment CHC 21 . Serum alanine aminotransferase ( ALT ) concentration &gt; 5 x ULN 22 . Alpha Fetoprotein ( AFP ) ≥ ULN , unless absence hepatic mass lesion demonstrate ultrasound within screen period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>